Novartis's Onbrez Breezhaler approved in EU for COPD
08 December 2009
Katie McQue
Please Login to read the full article.
08 December 2009
Katie McQue
katie.mcque@informa.com
Novartis's bronchodilator Onbrez Breezhaler (indacaterol; formerly QAB149) has been approved in the EU as a once-daily maintenance treatment for chronic obstructive pulmonary disease (COPD) in adults, following a positive CHMP opinion in September.
The company plans to launch the long-acting...
Please Login to read the full article.
RELATED CONTENT
NEWS
- Novartis' indacaterol plus Spiriva gives combined efficacy boost in COPD
- US FDA panel backs Novartis lower dose COPD drug, but rejects higher dose
- Japanese COPD alliance with Novartis marks new ground for Eisai
- US FDA delays decision on Novartis COPD drug, giving Forest drug a leap ahead
EVENTS
28 February 2012
Pestana Chelsea Bridge Hotel London
04 March 2012
The Marriott World Center, Orlando, Florida
26 March 2012
Copenhagen, Denmark
JOB OF THE WEEK
Promote your vacancy here
